Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Drug Discov Today ; 28(11): 103772, 2023 Nov.
Article in English | MEDLINE | ID: mdl-37717933

ABSTRACT

High-throughput computational platforms are being established to accelerate drug discovery. Servier launched the Patrimony platform to harness computational sciences and artificial intelligence (AI) to integrate massive multimodal data from internal and external sources. Patrimony has enabled researchers to prioritize therapeutic targets based on a deep understanding of the pathophysiology of immuno-inflammatory diseases. Herein, we share our experience regarding main challenges and critical success factors faced when industrializing the platform and broadening its applications to neurological diseases. We emphasize the importance of integrating such platforms in an end-to-end drug discovery process and engaging human experts early on to ensure a transforming impact.


Subject(s)
Artificial Intelligence , Drug Discovery , Humans , Research Personnel
2.
Acta Neuropathol Commun ; 9(1): 177, 2021 11 02.
Article in English | MEDLINE | ID: mdl-34727983

ABSTRACT

In Alzheimer's disease and related tauopathies, trans-synaptic transfer and accumulation of pathological tau from donor to recipient neurons is thought to contribute to disease progression, but the underlying mechanisms are poorly understood. Using complementary in vivo and in vitro models, we examined the relationship between these two processes and neuronal clearance. Accumulation of p62 (a marker of defective protein clearance) correlated with pathological tau accumulation in two mouse models of tauopathy spread; Entorhinal Cortex-tau (EC-Tau) mice where tau pathology progresses in time from EC to other brain regions, and PS19 mice injected with tau seeds. In both models and in several brain regions, p62 colocalized with human tau in a pathological conformation (MC1 antibody). In EC-Tau mice, p62 accumulated before overt tau pathology had developed and was associated with the presence of aggregation-competent tau seeds identified using a FRET-based assay. Furthermore, p62 accumulated in the cytoplasm of neurons in the dentate gyrus of EC-Tau mice prior to the appearance of MC1 positive tauopathy. However, MC1 positive tau was shown to be present at the synapse and to colocalize with p62 as shown by immuno electron microscopy. In vitro, p62 colocalized with tau inclusions in two primary cortical neuron models of tau pathology. In a three-chamber microfluidic device containing neurons overexpressing fluorescent tau, seeding of tau in the donor chamber led to tau pathology spread and p62 accumulation in both the donor and the recipient chamber. Overall, these data are in accordance with the hypothesis that the accumulation and trans-synaptic spread of pathological tau disrupts clearance mechanisms, preceding the appearance of obvious tau aggregation. A vicious cycle of tau accumulation and clearance deficit would be expected to feed-forward and exacerbate disease progression across neuronal circuits in human tauopathies.


Subject(s)
Brain/pathology , Neurons/pathology , Sequestosome-1 Protein/metabolism , Tauopathies/pathology , Animals , Brain/metabolism , Disease Progression , Humans , Mice , Neurons/metabolism , Tauopathies/metabolism
3.
EMBO J ; 37(15)2018 08 01.
Article in English | MEDLINE | ID: mdl-29941661

ABSTRACT

LINE-1 mobile genetic elements have shaped the mammalian genome during evolution. A minority of them have escaped fossilization which, when activated, can threaten genome integrity. We report that LINE-1 are expressed in substantia nigra ventral midbrain dopaminergic neurons, a class of neurons that degenerate in Parkinson's disease. In Engrailed-1 heterozygotes, these neurons show a progressive degeneration that starts at 6 weeks of age, coinciding with an increase in LINE-1 expression. Similarly, DNA damage and cell death, induced by an acute oxidative stress applied to embryonic midbrain neurons in culture or to adult midbrain dopaminergic neurons in vivo, are accompanied by enhanced LINE-1 expression. Reduction of LINE-1 activity through (i) direct transcriptional repression by Engrailed, (ii) a siRNA directed against LINE-1, (iii) the nucleoside analogue reverse transcriptase inhibitor stavudine, and (iv) viral Piwil1 expression, protects against oxidative stress in vitro and in vivo We thus propose that LINE-1 overexpression triggers oxidative stress-induced DNA strand breaks and that an Engrailed adult function is to protect mesencephalic dopaminergic neurons through the repression of LINE-1 expression.


Subject(s)
DNA Breaks , Dopaminergic Neurons/pathology , Homeodomain Proteins/genetics , Long Interspersed Nucleotide Elements/genetics , Oxidative Stress/genetics , Animals , Argonaute Proteins/genetics , Cell Line , DNA Damage/genetics , Dopaminergic Neurons/metabolism , HEK293 Cells , Humans , Mice , Mice, Transgenic , RNA Interference , RNA, Small Interfering/genetics , Regulatory Elements, Transcriptional/genetics , Substantia Nigra/metabolism
4.
Neural Plast ; 2016: 6097107, 2016.
Article in English | MEDLINE | ID: mdl-26881122

ABSTRACT

A number of transcription factors, including En1/2, Foxa1/2, Lmx1a/b, Nurr1, Otx2, and Pitx3, with key roles in midbrain dopaminergic (mDA) neuron development, also regulate adult mDA neuron survival and physiology. Mouse models with targeted disruption of some of these genes display several features reminiscent of Parkinson disease (PD), in particular the selective and progressive loss of mDA neurons in the substantia nigra pars compacta (SNpc). The characterization of these animal models has provided valuable insights into various mechanisms of PD pathogenesis. Therefore, the dissection of the mechanisms and survival signalling pathways engaged by these transcription factors to protect mDA neuron from degeneration can suggest novel therapeutic strategies. The work on En1/2-mediated neuroprotection also highlights the potential of protein transduction technology for neuroprotective approaches in PD.


Subject(s)
Disease Models, Animal , Dopaminergic Neurons/metabolism , Parkinson Disease/genetics , Transcription Factors/genetics , Animals , Mesencephalon/metabolism , Mice , Parkinson Disease/metabolism , Pars Compacta/metabolism , Signal Transduction
5.
FEBS Lett ; 589(24 Pt A): 3786-94, 2015 Dec 21.
Article in English | MEDLINE | ID: mdl-26459030

ABSTRACT

The homeoprotein Engrailed (Engrailed-1/Engrailed-2, collectively En1/2) is not only a survival factor for mesencephalic dopaminergic (mDA) neurons during development, but continues to exert neuroprotective and physiological functions in adult mDA neurons. Loss of one En1 allele in the mouse leads to progressive demise of mDA neurons in the ventral midbrain starting from 6 weeks of age. These mice also develop Parkinson disease-like motor and non-motor symptoms. The characterization of En1 heterozygous mice have revealed striking parallels to central mechanisms of Parkinson disease pathogenesis, mainly related to mitochondrial dysfunction and retrograde degeneration. Thanks to the ability of homeoproteins to transduce cells, En1/2 proteins have also been used to protect mDA neurons in various experimental models of Parkinson disease. This neuroprotection is partly linked to the ability of En1/2 to regulate the translation of certain nuclear-encoded mitochondrial mRNAs for complex I subunits. Other transcription factors that govern mDA neuron development (e.g. Foxa1/2, Lmx1a/b, Nurr1, Otx2, Pitx3) also continue to function for the survival and maintenance of mDA neurons in the adult and act through partially overlapping but also diverse mechanisms.


Subject(s)
Dopaminergic Neurons/metabolism , Homeodomain Proteins/physiology , Nerve Tissue Proteins/physiology , Parkinson Disease/metabolism , Animals , Humans , Mice, Transgenic , Mitochondria/metabolism , Parkinson Disease/pathology
6.
Cell Rep ; 13(2): 242-50, 2015 Oct 13.
Article in English | MEDLINE | ID: mdl-26411690

ABSTRACT

Engrailed homeoproteins are expressed in adult dopaminergic neurons of the substantia nigra. In Engrailed1 heterozygous mice, these neurons start dying at 6 weeks, are more sensitive to oxidative stress, and progressively develop traits similar to those observed following an acute and strong oxidative stress inflected to wild-type neurons. These changes include DNA strand breaks and the modification (intensity and distribution) of several nuclear and nucleolar heterochromatin marks. Engrailed1 and Engrailed2 are biochemically equivalent transducing proteins previously used to antagonize dopaminergic neuron death in Engrailed1 heterozygous mice and in mouse models of Parkinson disease. Accordingly, we show that, following an acute oxidative stress, a single Engrailed2 injection restores all nuclear and nucleolar heterochromatin marks, decreases the number of DNA strand breaks, and protects dopaminergic neurons against apoptosis.


Subject(s)
Dopaminergic Neurons/metabolism , Homeodomain Proteins/pharmacology , Nerve Tissue Proteins/pharmacology , Neuroprotective Agents/pharmacology , Oxidative Stress , Substantia Nigra/metabolism , Amino Acid Sequence , Animals , Apoptosis , DNA Damage , Heterochromatin/genetics , Homeodomain Proteins/administration & dosage , Homeodomain Proteins/genetics , Infusions, Intraventricular , Mice , Molecular Sequence Data , Nerve Tissue Proteins/administration & dosage , Neuroprotective Agents/administration & dosage , Substantia Nigra/cytology
SELECTION OF CITATIONS
SEARCH DETAIL
...